Journal article

Optic Nerve Magnetisation Transfer Ratio after Acute Optic Neuritis Predicts Axonal and Visual Outcomes

Yejun Wang, Anneke van der Walt, Mark Paine, Alexander Klistorner, Helmut Butzkueven, Gary F Egan, Trevor J Kilpatrick, Scott C Kolbe



Awarded by National MS Society

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

This research was supported by the National MS Society (grant RG4211A4/2#) and the National Health and Medical Research Council of Australia (grant 628415). The authors received small unrestricted grants from Bayer Australia, Biogen Idec, Merck Serono and GlaxoSmithKline. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Dr. van der Walt has received travel support from Bayer Australia and Sanofi Aventis. She has received unrestricted grants from Bayer Asutralia and Biogen Idec. Dr. Klistorner is supported by an unrestricted grant from Biogen Idec. Dr. Butzkueven has served on scientific advisory boards for Biogen Idec, Novartis and Sanofi-Aventis and has received conference travel support from Novartis, Biogen Idec and Sanofi Aventis. He serves on steering committees for trials conducted by Merck Serono, Biogen Idec and Novartis. Dr. Butzkueven has received research support from Merck Serono, Novartis and Biogen Idec in his capacity as honorary chair of the MSBase Foundation. Dr. Kilpatrick has served on scientific advisory boards for GlaxoSmithKline, Neurosciences Victoria and the Victorian Neurotrauma Initiative; has received funding for travel from Bayer Schering pharma, Sanofi Aventis and Merck Serono; served on the editorial board of Therapeutic Advances in Neurological Disorders; is listed as an inventor on patents re: HIV test kit method for detecting anti-HIV-1 antibodies in saliva; A method of modulating cell survival and reagents useful for the same; Methods for the treatment and prophylaxis of demyelinating disease; and Method of treatment in the field of inflammatory neurodegeneration; and receives research support from Bayer Schering Pharma, Biogen IDEC. Dr. Egan serves on an ARC college of experts panel for which he receives personal compensation, he is a member of the Neurosciences Victoria scientific advisory board; he has received travel expenses and/or honoraria for lectures or educational activities not funded by industry; he is an associate editor of Human Brain Mapping, he serves on the editorial boards of Neuroimage and the Journal of Imaging Technology.